Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy

Cholesterol Treatment Trialists’ Collaboration*

Abstract
Background: Meta-analyses of individual-level data from randomised trials are often required to detect clinically worthwhile effects. The Cholesterol Treatment Trialists’ Collaboration, which includes data from numerous large long-term statin trials, is conducting a review of the effects of statin therapy on all adverse events collected in those trials. This article describes the approaches used and challenges faced to systematically capture and categorise the data.

Methods: Protocols, statistical analysis plans, case report forms, clinical study reports and datasets were obtained, reviewed and checked. Relevant baseline and follow-up data from each trial was then reorganised into standardised formats based upon the Clinical Data Interchange Standards Consortium Study Data Tabulation Model. Adverse event data were organised and coded (automatically or, where necessary, manually) according to a common medical dictionary based upon the Medical Dictionary for Regulatory Activities.

Results: Data from 23 double-blind statin trials and 5 open-label statin trials were provided, either through direct data transfer or through online access platforms. Together, these trials provided 845 datasets containing over 38 million records relating to 30,495 study variables and 181,973 randomised participants. Of the 46 Clinical Data Interchange Standards Consortium Study Data Tabulation Model domains that could potentially have been used to organise the data, the 13 most relevant to the project were identified and utilised, including 6 domains related to post-randomisation adverse events. Nearly 1.2 million adverse events were extracted and mapped to over 45,000 unique adverse event terms. Of these adverse events, 99% were coded to a Medical Dictionary for Regulatory Activities ‘lower level term’, with the remainder coded to a ‘higher level term’ or, very rarely, only a ‘higher level group term’.

Conclusion: In this meta-analysis of adverse event data from the large randomised trials of statins, approaches based on common standards for data organisation and classification have provided a resource capable of allowing reliable and rapid evaluation of any previously unknown benefits or hazards of statin therapy.
Introduction

The vast majority of interventions have only moderate effects on disease outcomes and hence are impossible to evaluate without careful study. Any clinical study where the main objective is to assess moderate treatment effects must therefore ensure that any biases and any random errors that are inherent in its design are both substantially smaller than the anticipated effect size. The only way to guarantee the avoidance of moderate biases is to randomise while the only way to guarantee avoidance of moderate random errors is to study large numbers of outcomes. Large-scale randomised controlled trials (RCTs) are therefore typically needed when comparing the effect(s) of any new treatment with a control group. Even then, single randomised controlled trials are rarely large enough to answer all the questions we would like to ask. Consequently, individual participant data meta-analyses of randomised trials are often used to systematically assess the effects of a particular treatment.

The Cholesterol Treatment Trialists’ Collaboration includes large-scale (≥1000 participants), long-term (≥2 years scheduled treatment duration) unconounded, randomised controlled trials of lipid intervention therapies. To date, reports have focussed on the effects of statin therapy on major vascular events, cause-specific mortality and cancer. In particular, analyses have shown that reduction of low-density lipoprotein cholesterol with a statin reduces the risk of major vascular events without any increase in the risk of non-vascular causes of death or of site-specific cancer in a wide range of people. The results from the Cholesterol Treatment Trialists’ Collaboration have led to significant changes in clinical practice, but in recent years, concerns have been raised that statins may cause a range of other adverse effects (particularly, muscle symptoms). To address these concerns, in 2016, we published a protocol to significantly extend the previous dataset to provide a more complete understanding of the nature and magnitude of the effects of statins.

In particular, all adverse events reported during each trial were requested, in addition to variables that might help in the interpretation of particular events (such as non-trial medications and laboratory results).

 Undertaking individual participant data meta-analyses of RCTs can be complex due to the volume of data involved and differences between trials in the way data are collected and organised. Even seemingly similar RCTs in a single therapeutic area can vary substantially in relation to the type and range of data collected. While some trials make use of widely recognised event-coding systems such as the International Classification of Diseases or the Medical Dictionary for Regulatory Activities (MedDRA), versions of such coding systems vary, while other trials may employ country-specific or older dictionary types (such as UK Read codes) or custom codes. In addition, although many investigators remain amenable to the direct transfer of their data to a central coordinating centre, others require the use of data-sharing platforms, which may place restrictions on the software available for analysis and/or the way in which the results of analyses can be extracted.

The purpose of this article is to describe the approaches we used to harmonise the complex, heterogeneous and extensive individual participant data received into a single analysable dataset, the challenges faced in doing so, and the solutions devised to overcome these challenges.

Methods

The processes through which data (and other associated materials) from each trial were requested and organised (in advance of statistical analyses of the effects of statin therapy on adverse events) are summarised in Figure 1. For each trial, we requested the following: information related to how adverse events were sought, including high-level documentation such as trial protocols; blank copies of the trial case report forms and information on any coding systems used; any available existing tabulations of adverse event data (e.g. in published articles or elsewhere) and all individual-level datasets containing information on adverse events (including the time from randomisation to each adverse event); the timing of and reasons for stopping study treatment; co-medication data and laboratory data or data on physical measurements (e.g. body mass index, blood pressure) or lifestyle characteristics (e.g. smoking). Most trials sent this information directly to the co-ordinating centre in Oxford for storage and processing on secure servers. However, for some trials, this information was made available through the granting of access to a secure online data-sharing platform. These data-sharing platforms, which were only accessible to approved users in the coordinating centre, allowed detailed interrogation and reorganisation of the datasets, but restricted the download of information to summary level results of
analyses following submission of a specific data export request. The requirement to use data-sharing platforms for some trials also meant that the planned meta-analyses of the effects of statin therapy on adverse events would necessarily need to be done using a ‘two-stage’ approach.

The project is covered by a UK Research Ethics Committee approval (reference 21/SC/0071).

Development of a common data format based on Clinical Data Interchange Standards Consortium Study Data Tabulation Model

Existing global standards for data harmonisation were explored for potential use, with the Clinical Data Interchange Standards Consortium Study Data Tabulation Model (CDISC SDTM) selected as the preferred system due, in part, to its current wide use in RCTs. The CDISC SDTM Implementation Guide describes groups of tabulation datasets (or domains) available for specific data types. All variables within a domain are subdivided into three categories (required, expected and permissible), with these definitions explaining the importance of the variable within the domain. CDISC also allows for ‘customised’ project-specific CDISC SDTM domains or variables to be created.

CDISC SDTM version 3.2 (and version 1.4 of its Implementation Guide) was the version in place at the time of commencement of the project. On review of all available domains in relation to the types of data likely to be received, the study team thought it inappropriate to follow CDISC SDTM rigidly, particularly given that most of the eligible trials included in the project substantially pre-dated CDISC SDTM’s introduction. A pragmatic streamlined approach was therefore adopted, with 13 out of the available 46 domains being considered sufficient for the completion of the CTT IPD meta-analysis project (Table 1). These 13 domains were as follows: Adverse Events, Clinical Events, Death Details, Procedures, Healthcare Encounters, Laboratory Test Results, Medical History, Procedures, Substance Use, Subject Visit and Vital Signs (Full details of the information captured by these 13 domains can be found in Webtable 1 in the Supplemental Material).

A streamlined approach was also adopted to utilisation of variables within each SDTM domain. For example, only 13 types of laboratory test were considered as essential for the analyses and created in the laboratory domain (Table 1). Similarly, for the substance use domain, only baseline smoking status and alcohol consumption were included, while for the medical history domain, only history of cardiovascular diseases and diabetes were utilised.

Use of a common event-coding dictionary based on MedDRA

Of the 13 SDTM domains considered to be relevant, six (adverse events, clinical events, death details, procedures, healthcare encounters and exposure) pertain to...
the capture of outcomes that could reasonably be considered to be adverse events when assessing the potential effects of statin therapy. A single categorisation and coding system for adverse events was then needed which would allow for detailed and consistent assessments of any type of adverse event (or group of adverse events) in each trial and, through meta-analyses, across all trials. We selected MedDRA as the reference medical terminology dictionary to harmonise the numerous event-coding formats used in the included trials into a single common language. MedDRA encompasses >77,000 different ‘terms’ based on a five-tiered hierarchical structure ranging from the most granular ‘Lowest Level Term’ to the very general ‘System Organ Class’ (Table 2).

Adverse event terms (including those given as reasons for stopping study treatment as determined from the SDTM exposure domain) were coded, blind to treatment allocation, to MedDRA version 20.0 (the version in use at the time of commencement of the project). Webtable 2 (Supplemental Material) presents the number of available terms at each of the hierarchical levels in MedDRA version 20.0, organised by system organ class. A computer program was devised to ensure that adverse event terms that directly mapped to an existing MedDRA V20.0 term would be included in analyses not only of that one category, but also of all relevant higher adverse event categories. Initially, a direct match was sought at the lower level term, but if no exact match was found, matches were attempted at higher MedDRA levels (initially at the higher level term, and if that failed then at the higher level group term). For terms that did not directly encode in this way, mapping was done manually by a research team overseen by clinicians. Initially, such terms were checked for obvious errors such as simple typographical errors or changes in

| SDTM domain   | Description                                                                                                                                                                                                                   |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adverse events| Adverse events which may be reported either as free text or as terms created from a coding system (e.g. MedDRA or International Classification of Diseases).                                                                                                         |
| Clinical events| Trial-specific non-fatal events which were not classified as adverse events.                                                                                                                                               |
| Co-medication | Concomitant and prior medications/therapies used by the participant. Examples are the concomitant medications/therapies given on an as needed basis and the usual background medications/therapies given for a condition.                |
| Death details | Any fatal events regardless of cause.                                                                                                                                                                                     |
| Demographics  | The parent domain for all other domains including a set of essential standard variables that describe each participant in the clinical study. Examples are the participants’ characteristics at baseline (e.g. treatment allocation, age and race). |
| Exposure      | Reasons for stopping (or adjusting) study treatment. For our purposes, only adverse events resulting in stopping (or adjusting) study treatment were sought.                                                                                             |
| Healthcare encounters | Inpatient and outpatient healthcare events (e.g. hospitalisations, nursing home stay, rehabilitation facility stays and ambulatory surgery).                                                                                  |
| Laboratory test results | Laboratory test findings including, but not limited to haematology, clinical chemistry and urinalysis data. For our purposes, only the following laboratory tests were captured: (1) alanine aminotransferase, (2) aspartate aminotransferase, (3) creatine kinase, (4) glucose in blood, (6) high-density lipoprotein cholesterol, (7) low-density lipoprotein cholesterol, (8) triglycerides, (9) total cholesterol, (10) creatinine concentration (serum), (11) estimated glomerular filtration rate, (12) glycosylated haemoglobin and (13) platelets (thrombocytes). |
| Medical history | The participant’s prior history at the start of the trial (e.g. general medical history, gynaecological history and primary diagnosis).                                                                                      |
| Procedures    | Details describing a participant’s therapeutic and diagnostic procedures (e.g. coronary artery bypass graft, cataract surgery or hip replacement).                                                                              |
| Substance use | Substance use information that may be used to assess the efficacy and/or safety of therapies that look to mitigate the effects of chronic substance use. For our purposes, only smoking status and alcohol consumption at baseline were collected. |
| Subject visit  | Information about the timing of participant visits that is otherwise spread over domains that include the visit variables. For our purposes, the subject visit domain was created only when imputation methods were required for timing variables. |
| Vital signs    | Measurements including but not limited to blood pressure, temperature, respiration, body surface area, body mass index, height and weight. For our purposes, only the following measurements were captured: (1) systolic blood pressure, (2) diastolic blood pressure, (3) heart rate, (4) body mass index, (5) height, (6) weight and (7) waist circumference. |

CDISC: Clinical Data Interchange Standards Consortium, SDTM: Study Data Tabulation Model; CTT: Cholesterol Treatment Trialists; MedDRA: Medical Dictionary for Regulatory Activities.
word ordering that precluded direct coding. If such basic corrections still failed to yield a direct MedDRA match, a more detailed manual mapping assessment was undertaken, following a coding guidance document developed for the project based upon the MedDRA coding guidance. Such detailed assessment was particularly required when events had been coded as ‘free text’. To ensure consistency, all adverse events were coded by at least two members of the research team, with any discrepancies resolved by discussion. In addition, to ensure medical accuracy, manual mapping of adverse events corresponding to major pre-specified outcomes (such as muscle outcomes and diabetes) was done by two clinicians. Periodic clinician subsampling of all other encoded adverse events was also undertaken.

**Organisation of trial data prior to analysis**

Included trials were categorised into four main groups: double-blind trials of statin therapy versus placebo, open-label trials of statin versus control or usual care, double-blind (i.e. ‘double-dummy’) trials of more intensive versus less intensive statin therapy and open-label trials of more intensive versus less intensive statin therapy.

**Results**

**Summary of received data**

Data from 28 large-scale clinical trials contributed to this individual participant data meta-analysis. Eight hundred and forty-five datasets were received containing over 38 million records, resulting in 30,495 variables (Table 3). The volume of the data for each trial was driven more by the structure of the questionnaires for each trial and how trialists had structured their own data rather than just the number of participants in the trial. Most trials provided a combination of raw data (i.e. exactly as collected) and derived data (i.e. whereby data cleaning had been applied by the trialists, such as when pre-specified outcomes had been clinically adjudicated). Only two trials provided data in CDISC SDTM format (having applied such formatting retrospectively after completion of the trial).

**Data harmonisation**

The 13 SDTM domains chosen for use in the project yielded a total of 121 variables (of which 13 were additional supplementary variables created specifically for our purposes) (see Weblink 1). However, some trials did not require the creation of all of the 13 selected SDTM domains based on the structure of their data. For example, for trials which reported all of their adverse events (i.e. including fatal and non-fatal study outcomes, hospitalisation and medical procedures) in a single dataset, the creation of the single SDTM adverse event domain was considered sufficient to harmonise such data.

**Mapping of adverse events to MedDRA**

The main medical terminology used to encode adverse events in the received trials varied. Seventeen of the 28 trials encoded their data using different versions of MedDRA (Table 3), although in some cases the MedDRA version was not stipulated. All of these 17 trials mapped their adverse event terms to a MedDRA lower level term, although a small subset of events from 3 of the trials were received at the higher level term or higher level group term level (because of a fear by the data providers that provision at the lower level term

| MedDRA hierarchical level     | Description                                                                 | Total number of available terms |
|-------------------------------|-----------------------------------------------------------------------------|---------------------------------|
| Lower level term              | A reflection of how observations might be reported in practice, for example, a verbatim term. Each lower level term is linked to only one preferred term. | 77,248                          |
| Preferred term                | A single descriptor such as a symptom, sign, disease diagnosis, investigation or procedure. Each preferred term has at least one lower level term (itself) as well as synonyms and lexical variants (e.g. abbreviations, different word order). | 22,499                          |
| Higher level term             | A group of preferred terms that are related based on anatomy, pathology, physiology, aetiology or function. | 1553                            |
| Higher level group term       | Related higher level terms are linked to higher level group terms based on anatomy, pathology, physiology, aetiology, or function. The final level of the hierarchy where higher level group terms are grouped by aetiology (e.g. infections and infestations), manifestation site (e.g. gastrointestinal disorders) or purpose (e.g. surgical and medical procedures). There is also a system organ class to contain issues pertaining to products and one to contain social circumstances. | 326                             |
| System organ class            |                                                                                           | 27                              |

Table 2. The five-tiered hierarchical structure of Medical Dictionary for Regulatory Activities (MedDRA).
Table 3. Characteristics of the 23 double-blind and 5 open-label statin trials.

| Study        | Year of publication of primary results | Number of participants | Treatment comparison (mg/day) | Median follow-up (years) | Meta-data | Total number of datasets | Records | Variables | Main medical terminology | Adverse event terms |
|--------------|----------------------------------------|------------------------|-------------------------------|--------------------------|-----------|--------------------------|---------|-----------|--------------------------|---------------------|
|              |                                        |                        |                               |                          |           |                          |         |           |                          |                     |
| Statin vs placebo, double-blinded trials |
| 4S           | 1994                                   | 4444                   | S20-40 vs placebo             | 5.4                      | FP        | 5                        | 116,502 | 147       | MedDRA*                  | 33,661 1390        |
| WOSCOPS      | 1995                                   | 6595                   | P40 vs placebo                | 4.8                      | FP        | 23                       | 671,759 | 509       | BMS ICD-9                | 78,673 7978        |
| CARE         | 1996                                   | 4159                   | P40 vs placebo                | 4.9                      | FPR       | 9                        | 1,849,516 | 275     | BMS ICD-9                | 91,635 753         |
| APCAPS/TexCAPS | 1998                                  | 6605                   | L20-40 vs placebo             | 5.0                      | P         | 5                        | 995,156 97 |         | MedDRA*                  | 8143 770          |
| LIPID        | 1998                                   | 9014                   | P40 vs placebo                | 5.9                      | FPR       | 28                       | 1,347,182 | 592     | ICD-9                    | 57,636 7075        |
| LIPS         | 2002                                   | 1677                   | P80 vs placebo                | 4.0                      | FPR       | 61                       | 537,144 | 1145      | ICD-10                   | 8867 2392         |
| HPS          | 2002                                   | 20,536                 | S40 vs placebo                | 5.2                      | FP        | 28                       | 8,152,101 | 392     | MedDRA 14                | 76,986 2378        |
| PROSPER      | 2002                                   | 5804                   | P40 vs placebo                | 3.3                      | FP        | 11                       | 628,189 | 485       | Modified ICD-9           | 131,598 848        |
| ASCOT-LLA    | 2003                                   | 10,240                 | A10 vs placebo                | 3.3                      | FP        | 10                       | 710,266 | 466       | ICD-9                    | 42,294 1896        |
| ALERT        | 2003                                   | 2102                   | P40 vs placebo                | 5.5                      | FPR       | 79                       | 1,069,747 | 5654   | MedDRA 11                | 27,114 3589        |
| CARDS        | 2004                                   | 2838                   | A10 vs placebo                | 4.2                      | FP        | 18                       | 988,712 | 522       | MedDRA 11                | 26,485 1390        |
| 4D           | 2005                                   | 1255                   | A20 vs placebo                | 2.7                      | FP        | 21                       | 302,442 | 632       | MedDRA 11                | 6758 461           |
| ASPEN        | 2006                                   | 2410                   | A10 vs placebo                | 4.0                      | FP        | 18                       | 472,820 | 379       | MedDRA 11                | 20,323 2861        |
| SPARCL       | 2006                                   | 4731                   | A80 vs placebo                | 4.9                      | FP        | 14                       | 900,713 | 512       | MedDRA 11                | 38,813 3539        |
| CORONA       | 2007                                   | 4984                   | R10 vs placebo                | 2.8                      | FPR       | 62                       | 2,155,519 | 1716   | MedDRA 10                | 28,899 3450        |
| JUPITER      | 2008                                   | 16,714                 | R20 vs placebo                | 1.9                      | FPR       | 33                       | 1,540,095 | 2428   | MedDRA 11.1              | 73,526 5731        |
| GISSI-HF     | 2008                                   | 4574                   | R10 vs placebo                | 3.9                      | F         | 10                       | 208,489 | 169       | MedDRA 15.1              | 28,701 537         |
| AURORA       | 2009                                   | 2555                   | R10 vs placebo                | 3.9                      | FPR       | 42                       | 724,490 | 1273      | MedDRA 11.1              | 39,512 4013        |
| HOPE-3       | 2016                                   | 12,705                 | R10 vs placebo                | 5.6                      | FP        | 170                      | 1,415,309 | 6213   | MedDRA 17.1              | 70,651 7631        |
| Subtotal     |                                        | 123,942                |                               |                          |           |                          | 646     | 24,786,151 | 23,606                 | 890,273 40,221     |
| Statin versus other control/usual care, open-label trials |
| POST-CABG    | 1997                                   | 1351                   | L40-80 vs L2.5-5              | 4.3                      | FP        | 83                       | 227,740 | 2821      | None                     | 37,164 650         |
| GISSI-P      | 2000                                   | 4271                   | P20 vs no treatment           | 1.9                      | FP        | 1                        | 4271 | 795    | ICD-9                    | 2777 228           |
| ALLHAT-LLT   | 2002                                   | 10,355                 | P40 vs no treatment           | 4.7                      | FP        | 10                       | 381,498 | 103    | ICD-9 ICD-10              | 9932 115           |
| ALLIANCE     | 2004                                   | 2442                   | A10-80 vs usual care          | 4.5                      | FP        | 15                       | 136,557 | 344    | MedDRA 11                | 3717 1334          |
| Subtotal     |                                        | 18,419                 |                               |                          |           |                          | 109    | 750,066 4063 |                     | 53,590 2311       |
| More vs less statin, double-blinded trials |
| PROVE-IT     | 2004                                   | 4,162                  | A80 vs P40                    | 2.1                      | FP        | 24                       | 603,289 | 1,161   | ICD-9                    | 25,600 1551        |
| A to Z       | 2004                                   | 4,497                  | S40 then S80 vs placebo       | 2.0                      | FP        | 10                       | 386,787 | 405    | MedDRA*                   | 4615 561           |
| TNT          | 2005                                   | 10,001                 | A80 vs A10                    | 5.0                      | FP        | 20                       | 2,676,152 | 624     | MedDRA 11                | 93,583 3735        |
| SEARCH       | 2010                                   | 12,064                 | S80 vs S20                    | 7.0                      | FP        | 25                       | 7,341,699 | 344     | MedDRA 14                | 61,379 1303        |
| Subtotal     |                                        | 30,724                 |                               |                          |           |                          | 79     | 11,007,927 | 2534                  | 185,177 6210      |

(continued)
| Study       | Year of publication of primary results | Number of participants | Treatment comparison (mg/day) | Median follow-up (years) | Meta-data | Total number of Adverse event terms | Adverse event terms |
|------------|----------------------------------------|------------------------|-------------------------------|--------------------------|-----------|------------------------------------|---------------------|
| IDEAL      | 2005                                   | 8888                   | A40-80 vs S20-40              | 5                       | FP        | I1                                | MedDRA 13           |
| Subtotal   |                                        | 8888                   |                               |                          |           | 1,999,354                          | 292                 |
| Total      |                                        | 181,973                |                               |                          |           | 845                               | 38,543,498          |

S: simvastatin; P: pravastatin; L: lovastatin; F: fluvastatin; A: atorvastatin; R: rosvastatin; CRF: case report forms; CSP: clinical study protocol; CSR: clinical study report; ICD: International Classification of Diseases; 4S: Scandinavian Simvastatin Survival Study; WOSCOPS: West of Scotland Coronary Prevention Study; CARE: Cholesterol And Recurrent Events; AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study; LIPID: Long-term Intervention with Pravastatin in Ischaemic Disease; LIPS: Lescol Intervention Prevention Study; HPS: Heart Protection Study; PROSPECT: PROspective Study of Pravastatin in the Elderly at Risk; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial– Lipid Lowering Arm; ALERT: Assessment of Lescol in Renal Transplantation; CARDS: Collaborative Atorvastatin Diabetes Study; 4D: Die Deutsche Diabetes Dialyse Studie; ASPEN: Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus; SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels; CORONA: Controlled Rosuvastatin Multinational Trial in Heart Failure; JUPITER: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study group; GISSI-HF: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico; AURORA: A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiac Risk in Various Severity Distributions of End-Stage Renal Disease; HOPE-3: Heart Outcomes Prevention Evaluation-3 trial; Post-CABG: Post-Coronary Artery Bypass Graft; GISSI-P: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico; ALLHAT-LLT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ALLIANCE: Aggressive Lipid-Lowering Initiation Abates New Cardiac Events; PROVE-IT: Pravastatin or Atorvastatin Evaluation and Infection Therapy; A to Z: Aggrastat to Zocor; TNT: Treating to New Targets; SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine. IDEAL: Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.

A small number of participants in the AURORA (n = 218), CORONA (n = 27) and JUPITER (n = 1088) trials withdrew consent for use of their data post-trial, and hence, data from these participants are excluded. The ASCOT-LLA trial excludes 65 participants for whom data were not available due to protocol violations.

*aMost trials that used a medical terminology also provided some events in free text format. Some trials used more than one medical terminology.

*MedDRA version was unknown.
level could theoretically lead to the discovery of the identity of one or more study participants). Nine trials provided their adverse event data using International Classification of Diseases dictionaries (either version 9 or 10, or a modification or combination of these versions), while one trial used a combination of MedDRA and the International Classification of Diseases. One trial utilised no obviously recognisable coding system, and most trials appeared to use free text (events entered without use of a medical dictionary) on at least some occasions even if a medical coding dictionary was in place. Overall, the 28 trials included a total of approximately 1.2M adverse events corresponding to just over 45,000 unique terms.

Table 4 presents the total number of adverse event terms mapped directly across the hierarchical levels of MedDRA (V20.0).

| Type and MedDRA level of coding | Adverse events, N (%) | Unique terms |
|---------------------------------|-----------------------|--------------|
|                                 | Total                 | Unique terms |
| Automatically coded events       |                       |              |
| Lower level term                | 779,449 (65.6%)       | 11,965 (26.5%)|
| Higher level term               | 6216 (0.5%)           | 659 (1.5%)   |
| Higher level group term         | 820 (<0.1%)           | 1 (<0.1%)    |
| Subtotal                        | 786,485 (66.2%)       | 12,625 (27.9%)|
| Manually coded events           |                       |              |
| Lower level term                | 391,338 (32.9%)       | 32,458 (71.8%)|
| Higher level term               | 7571 (0.6%)           | 116 (0.3%)   |
| Higher level group term         | 2775 (0.2%)           | 31 (<0.1%)   |
| Subtotal                        | 401,684 (33.8%)       | 32,605 (72.1%)|
| Total                           | 1,188,169 (100%)      | 45,230 (100%)|

**Table 4.** Number of total and unique adverse event terms mapped across the hierarchical levels of MedDRA (V20.0).

*aTotal across all 28 trials. Numbers represent the number of adverse event terms provided by the trialists who were either automatically or manually coded into particular MedDRA levels (lower level, higher level and higher level group). bAs above, but counting the number of unique adverse event terms coded.

Adverse events were not coded to the MedDRA ‘Preferred Term’ level because each preferred term has an identical lower level term available. Thus, once all lower level terms have been coded, coding of preferred terms would provide no additional information.

Discussion

Our large individual participant data meta-analysis of the effects of statin therapy on all types of adverse event recorded in the large long-term statin trials presented significant data harmonisation challenges, even though all of the trials addressed a similar research question. These challenges largely related to the scale and heterogeneity of the data collected, but also challenges related to a requirement for us to use data-sharing platforms for some trials, as well as other challenges related to the fact that many of the statin trials published their results two or more decades ago.

Over the past two decades, standard methods for harmonising clinical trial data and outcomes have been introduced. Specifically, the CDISC released the first version of SDTM in 2005 as a standard structure for data tabulation from human clinical trials and non-clinical studies. This is now extensively used by the pharmaceutical industry and academia, and is required by some regulatory authorities such as the United States Food and Drug Administration or Japanese Pharmaceuticals and Medical Devices Agency when receiving data for licensing purposes.

However, there has been a paucity of detailed methodology for harmonising heterogeneous data from numerous different RCTs in individual participant data meta-analyses, especially those pre-dating the CDISC SDTM era (with relatively few trials appearing to have retrospectively fitted historic trial data to such standards). Despite a Preferred Reporting Items for a Systematic Review and Meta-analysis statement for individual participant data meta-analyses being published in 2015 which refers to the need to describe methods of standardising or translating variables within individual participant data datasets to ensure common scales or measurements across studies, details on how to do this in practice have been lacking. This means that researchers have typically had to develop their own methodology for harmonising numerous datasets in individual participant data meta-analyses by the
creation of bespoke systems to convert data from numerous RCTs into a single analysable dataset. This can be challenging and time-consuming.

The system we devised for use in the analysis of adverse events related to statin therapy presents one possible solution to this problem by incorporating methodology based on existing, widely recognised data standards devised by CDISC together with use of the MedDRA dictionary. The strengths of such a system include the transparency of the methodology which may help facilitate the interpretation and generalisability of the results. The ability to create ‘customised’ project-specific CDISC SDTM variables increased the project’s ability to handle very diverse data, while the hierarchical structure of MedDRA allowed mapping of terms at a variety of degrees of term specificity. This was potentially important given the range of terminologies received for reported adverse event terms, although most terms were able to be mapped at the lowest level of MedDRA (i.e. the lower level term) indicating that adverse events captured in our project were relatively granular in their specificity. The fact that terms which did not directly map had clinical oversight of their coding also meant that there was retention of reasonable closeness to original provided terms, which can be challenging if using natural language processing techniques.40,41

Limitations of our approach include the fact that despite deployment of streamlined, standards-based methods, the project still required considerable staff resource. Although the CDISC SDTM standard was used to organise and format the data, the corresponding CDISC Analysis Data Model to define datasets and metadata for analysis was not utilised due to analysis programs having been devised for our previous publications (meaning we did not need to explore such CDISC functionality in our project). However, use of CDISC Analysis Data Model methodology may well be worthwhile in future projects that do not have such an established history. Challenges encountered with the MedDRA dictionary included it not affording ready flexibility in terms of creation of project-specific custom codes for terms for which there was no obvious match. Although it is possible to ask MedDRA to add new terms or modify existing terms, these changes take time to approve which can be problematic for ongoing projects that use a specific version of MedDRA. In addition, ‘self-learning’ MedDRA mapping software is not currently available, meaning that such mapping can still be fairly resource intensive. In addition, although it is possible (and entirely reasonable) to adopt a two-stage meta-analysis approach for the assessment of the effects of statins on adverse events, the requirement to use data-sharing platforms for some trials does rule out the use of alternative one-stage meta-analysis approaches (which can offer additional flexibility over the two-stage approach).

In summary, through use of systems based upon the widely recognisable standards of CDISC SDTM and MedDRA, we have converted highly heterogeneous legacy data from the large long-term statin trials into one of the richest individual-level datasets in the world, able to address a pressing public health issue. The dataset generated by this project will not only act as a tool to address current concerns regarding statin therapy, but will also act as a resource to test any future hypotheses that may emerge about any other effects of this drug class. The methodological approaches we developed could be easily modified for use in other settings to robustly explore the full effects of widely used interventions.

Membership of the Cholesterol Treatment Trialists’ Collaboration

The Writing Committee members are as follows: Enti Spata*, Lisa Blackwell*, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Charlie Harper, Alistair Roddick, Nathan Samuel, Will Stevens, Karl Wallendszus, David Preiss, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Jonathan Emberson†, Christina Reith† (*equal first author and †equal last author).

Author affiliations:

Medical Research Council Population Health Research Unit, Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF.

Enti Spata, Lisa Blackwell, Kelly Davies, Heather Halls, Lisa Holland, Charlie Harper, Colin Baigent, Jonathan Emberson.

Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF

Kate Wilson, Alistair Roddick, Nathan Samuel, Will Stevens, Karl Wallendszus, David Preiss, Rory Collins, Christina Reith.

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW 2006, Australia.

Anthony Keech, John Simes.

Author contributions

E.S. and L.B. drafted the first version of the manuscript and J.E. and C.R. revised it. L.B., K.D., J.E., C.H., H.H., L.H., C.R., E.S., W.S., K.Wa., and K.Wi. conceived and designed the methodology. L.B., K.D., J.E., C.H., H.H., L.H., A.R., D.P., C.R., E.S., N.S.,
Acknowledgements

The authors thank all the participants who originally took part in the included trials, without whom this research would not be possible. The authors also like to thank Samantha Briggs and Clare Mathews for their valuable administrative assistance in preparing this report. Cholesterol Treatment Trials’ secretariat: J Armitage, C Baigent, E Barnes, L Blackwell, R Collins, K Davies, J Emberson, J Fulcher, H Halls, C Harper, W Herrington, L Holland, A Keech, A Kirby, B Mihaylova, R O’Connell, D Preiss, C Reith, J Simes, E Spata, K Wilson. Cholesterol Treatment Trials’ Collaborators: A to Z trial (phase Z): M Blazing, E Braunwald, J de Lemos, S Murphy; T Pedersen, M Pfeffer, H White, S Wiviott; AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study): M Clearfield, J R Downs, A Gotto, S Weis; ALERT (Assessment of Lescel in Renal Transplantation): B Fellström, H Holdaas (deceased), A Jardine, T R Pedersen; ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial): D Gordon, B Davis; C Furberg, R Grimm, S Pressel, J Probstfield, M Rahman, L Simpson; ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events): M Koren; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial): B Dahlöf, A Gupta, N Poulter, P Sever, H Wedel; ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus): R H Knopp (deceased); AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events): S Cobbe, B Fellström, H Holdaas (deceased), A Jardine, R Schmieder, F Zannad; CARDS (Collaborative Atorvastatin Diabetes Study): D J Betteridge (deceased), H M Colhoun, P N Durrington, J Fuller (deceased), G A Hitman, A Neil; CARE (Cholesterol And Recurrent Events Study): E Braunwald, B Davis, C M Hawkins, L Möy, M Pfeffer, F Sacks; CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure): J Kjekshus, H Wedel, J Wikstrand; 4D (Die Deutsche Diabetes Dialyse Studie): C Wanner, V Krane; GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico): Heart Failure and Prevention trials: M G Franzosi, R Latini, D Lucci, A Maggioni, R Marchioli, E B Nicholos, L Tavazzi, G Tognoni; HOPE-3: J Bosch, E Lonn, S Yusuf; HPS (Heart Protection Study): J Armitage, L Bowman, R Collins, A Keech, M Landray, S Parish, R Peto, P Sleight (deceased); IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid-lowering): J J P Kastelein, T R Pedersen; JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin): R Glynn, A Gotto, J J P Kastelein, W Koenig, J Macfadyen, P M Ridker; LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease): A Keech, S MacMahon, I Marschner, A Tonkin, J Shaw, J Simes, H White; LIPS (Lescel Intervention Prevention Study): P W Serruys; Post-CABG (Post-Coronary Artery Bypass Graft Study): G Knatterud (deceased); PROSPER (Prospective Study of Pravastatin in the Elderly at Risk): G Blauw, S Cobbe, J Ford, M Murphy, G J Blauw, P Macfarlane, C Packard, N Sattar J Shepherd, S Trompet; PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy): E Braunwald, C Cannon, S Murphy; SEARCH (Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine): R Collins, J Armitage, L Bowman, S Parish, R Peto, P Sleight (deceased); SPARCL (Stroke Prevention by Agressive Reduction in Cholesterol Levels): P Amarenco, K Welch; 4S (Scandinavian Simvastatin Survival Study): J Kjekshus, T Pedersen, L Wilhelmsen; TNT (Treating to New Targets): P Barter, A Gotto, J La Rosa; JJP Kastelein, J Shepherd; WOSCOPS (West of Scotland Coronary Prevention Study): S Cobbe, J Ford, S Kean, P Macfarlane, C Packard, M Roberston, N Sattar, J Shepherd, R Young. Other CTT Members: H Arashi, R Clarke, M Flather, S Gotto, U Goldbourt, J Hopewell, K Hovingh, G Kitsas, M Newman, M Sabatine, G Schwartz, L Smeeth, J Tobert, J Varigos, J Yamaguchi. Other members: R Flather, S Gotto, J Kastelein, C Newman, J Tobert, J Varigos, H White. Independent Oversight Panel: Emily Banks, Michael Blastland, Stephen Evans, Robert Temple, Peter Weissberg, Janet Wittes. Further details of membership of the Cholesterol Treatment Trials’ Collaboration can be found at: https://www.cttcollaboration.org

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The work of the Cholesterol Treatment Trials’ Collaboration has been funded by the Australian National Health and Medical Research Council (APP ID 1105467); the British Heart Foundation (PG/18/16/33570 and CH/1996001/9454); the European Community Biomed Programme (BMH-CT93-1552); the UK Medical Research Council (MC_UU_00017/4) and the National Institute for Health Research (17/140/02). Although individual trials that are contributing data to the analyses were funded by the pharmaceutical industry, as well as by charities and government organisations, the Cholesterol Treatment Trials’ Collaboration has not received grant funding from industry. Further details are available at www.cttcollaboration.org.

Data availability statement

Individual participant data from each contributing trial have been provided to the Cholesterol Treatment Trials’ Collaboration on the understanding that they would be used only for the purpose of the Cholesterol Treatment Trials’ meta-analyses and would not be released to others. Requests for such data should be made directly to the data custodians of each trial. The Cholesterol Treatment Trials’ data policy can be found on the website: https://www.cttcollaboration.org/about2.
Supplemental material

Supplemental material for this article is available online.

References

1. Collins R and MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. *Lancet* 2001; 357(9253): 373–380.
2. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019; 393(10170): 407–415.
3. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010; 376(9753): 1670–1681.
4. Cholesterol Treatment Trialists’ (CTT) Collaboration; Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS ONE* 2012; 7(1): e29849.
5. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-cholesterol lowering among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015; 385(9976): 1397–1405.
6. Cholesterol Treatment Trialists’ (CTT) Collaboration. Protocol for analyses of adverse event data from randomised controlled trials of statin therapy. *Am Heart J* 2016; 176: 63–69.
7. Levis B, Hattle M and Riley RD. PRIME-IPD SERIES Part 2. Retrieving, checking, and harmonizing data are underappreciated challenges in individual participant data meta-analyses. *J Clin Epidemiol* 2021; 136: 221–223.
8. World Health Organisation International Classification of Diseases: (ICD), https://icd.who.int/en/ (accessed 4 May 2022).
9. Medical Dictionary for Regulatory Activities (MedDRA), https://www.meddra.org/ (accessed 4 May 2022).
10. Study Data Tabulation Model (CDISC SDTM), https://www.cdisc.org/standards/foundational/sdtm (accessed 4 May 2022).
11. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005; 353(3): 238–248.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344(8934): 1383–1389.
13. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004; 292(11): 1307–1316.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. *JAMA* 1998; 279(20): 1615–1622.
15. Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvasstatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003; 361(9374): 2024–2031.
16. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). *JAMA* 2002; 288(23): 2998–3007.
17. Koren MJ and Hunninghake DB and on behalf of the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. *J Am Coll Cardiol* 2004; 44(9): 1772–1779.
18. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac outcomes trial – lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361(9364): 1149–1158.
19. Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEEN). *Diabetes Care* 2006; 29(7): 1478–1485.
20. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med* 2009; 360(14): 1395–1407.
21. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; 364(9435): 685–696.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. *N Engl J Med* 1996; 335(14): 1001–1009.
23. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2005; 357(22): 2248–2261.
24. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372(9645): 1231–1239.
25. GISSI Prevenzione Investigators. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge. *Ital Heart J* 2000; 1(12): 810–820.
26. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med* 2016; 374(21): 2021–2031.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360(9326): 7–22.
28. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 2005; 294(19): 2437–2445.
29. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; 359(21): 2195–2207.
30. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339(19): 1349–1357.
31. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; 287(24): 3215–3222.
32. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med* 1997; 336(3): 153–162.
33. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360(9346): 1623–1630.
34. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; 350(15): 1495–1504.
35. SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010; 376(9753): 1658–1669.
36. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006; 355(6): 549–559.
37. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005; 352(14): 1425–1435.
38. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; 333(20): 1301–1307.
39. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 2015; 313(16): 1657–1665.
40. Hong JC, Fairchild AT, Tanksley JP, et al. Natural language processing for abstraction of cancer treatment toxicities: accuracy versus human experts. *JAMIA Open* 2020; 3(4): 513–517.
41. Ly T, Pamer C, Dang O, et al. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology. *J Biomed Inform* 2018; 83: 73–86.